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Context: The pathogenic effect of mutations in the aryl hydrocarbon receptor interacting protein
(AIP) gene (AIPmuts) in pituitary adenomas is incompletely understood. We have identified the
primary mechanism of loss of function for missense AIPmuts.
Objective: This study sought to analyze themechanism/speed of protein turnover ofwild-type and
missense AIP variants, correlating protein half-life with clinical parameters.
Design and Setting:Half-life and protein–protein interaction experiments and cross-sectional analysis
of AIPmut positive patients’ data were performed in a clinical academic research institution.
Patients: Data were obtained from our cohort of pituitary adenoma patients and literature-re-
ported cases.
Interventions: Protein turnover of endogenous AIP in two cell lines and fifteen AIP variants over-
expressed in HEK293 cells was analyzed via cycloheximide chase and proteasome inhibition. Glu-
tathione-S-transferase pull-downandquantitativemass spectrometry identified proteins involved
in AIP degradation; results were confirmed by coimmunoprecipitation and gene knockdown.
Relevant clinical data was collected.
Main Outcome Measures: Half-life of wild-type and mutant AIP proteins and its correlation with
clinical parameters.
Results: EndogenousAIPhalf-lifewas similar inHEK293and lymphoblastoid cells (43.5and32.7h).AIP
variantswere divided into stable proteins (median, 77.7 h; interquartile range [IQR], 60.7–92.9 h), and
thosewith short (median, 27h; IQR, 21.6–28.7h) or very short (median, 7.7 h; IQR, 5.6–10.5h) half-life;
proteasomal inhibition rescued the rapid degradation of mutant proteins. The experimental half-life
significantly correlated with age at diagnosis of acromegaly/gigantism (r  0.411; P  .002). The
FBXO3-containing SKP1–CUL1–F-box protein complexwas identified as the E3 ubiquitin-ligase recog-
nizing AIP.
Conclusions: AIP is a stable protein, driven to ubiquitination by the SKP1–CUL1–F-box protein
complex. Enhanced proteasomal degradation is a novel pathogenic mechanism for AIPmuts, with
direct implications for the phenotype. (J Clin Endocrinol Metab 101: 3144–3154, 2016)
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Abbreviations: ACTB, beta-actin; AIP, aryl hydrocarbon receptor interacting protein; AIP-
mut, AIP mutation;CHX, cycloheximide; DMSO, dimethylsulfoxide; EBV-LC-AIP_WT, con-
trol subject; EBV-LC-AIP_p.R304*, Epstein Barr virus-transformed cell line of patient with
a heterozygous p.R304* AIPmut; IQR, interquartile range; K, degradation speed; KD,
knockdown; LOH, loss of heterozygosity; MAF, minor allele frequency; PPIase, peptidyl-
prolyl cis-trans isomerase; RING, really interesting new gene; SCF, SKP1-CUL1-F-box pro-
tein; TPR, tetratricopeptide; UPS, ubiquitin proteasome system; WB, Western blot; WT,
wild-type.
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Loss-of-functionmutations of the tumor suppressor arylhydrocarbon receptor interacting protein (AIP) gene
(AIPmuts) constitute the genetic basis of a subset of fa-
milial isolated pituitary adenomas and sporadic cases of
pituitary adenomas in young patients (1–3). Most of the
clinically relevant AIPmuts result in partial loss of the
tetratricopeptide (TPR) repeats and the final -7 helix of
the C-terminal TPR domain of the protein (truncating mu-
tations) (4), expectedly leading to unstable or nonexistent
proteins (5). Predicting, however, the pathogenic mecha-
nismsof themissensevariants canbechallenging.Theamino
acid sequence of the AIP TPR motifs is important to ensure
a correct interaction among residues in neighboring alpha
helices,aswellasadequateproteinfolding(6).Theconserved
amino acids located in the pocket between the TPRs 2 and 3
are essential for the interaction of AIPwithHSP90 (5).Mis-
sense mutations affecting residues involved in the folding of
theTPRdomaincouldresult inmisfoldedproteins,whichare
usuallyunstable, and in turnmay lead toa lossof their ability
to interact with other proteins (7).
Various approaches are available to determinewhether
nontruncating AIPmuts are indeed pathogenic or not.
Evaluating the segregation of the variant with the pheno-
type in large pedigrees with full medical history (8) would
be ideal, although incomplete penetrance and scarcity of
large families render this approachdifficult. The findingof
loss of heterozygosity (LOH) in the tumoral tissue could
support the pathogenic role of a variant (9), although
11q13 loss is commonly described in pituitary adenomas
(10, 11). The occurrence of a variant in hotspot residues as
a result of independent mutational events supports its
pathogenicity (12), although only few hotspots (amino
acids 81, 271, and 304) exist in AIP. In vitro functional
studies could be useful (8), but themost appropriate assay
to evaluate AIP variants has not yet been established.
In contrast, amino acid substitutions altering the struc-
ture, folding or stability of the protein, could lack an ob-
vious functional effect in in vitro studies. In combination
with in silico models (13), the evaluation of protein sta-
bility could help to determinewhether themutant proteins
are actually produced and if their turnover is normal, re-
gardless of their function (14). Protein half-life depends on
the rate of protein degradation and is usually decreased in
truncated ormisfolded proteins (15).We aimed to analyze
themechanism and speed of protein turnover of wild-type
(WT) AIP and AIP missense variants, correlating the pro-
tein half-life with the phenotype, using reduced in vitro
protein stability as a parameter suggesting loss or com-
promised function. Our data show correlation between in
vitro half-life data and the clinical parameters of the par-
ticular patients harboring missense variants.
Materials and Methods
Thedetailed experimental procedures and statistical analyses are
provided in Supplemental Methods. In brief, in AIP half-life ex-
periments, HEK293 and EBV-immortalized cells (derived from
a control subject [EBV-LC-AIP_WT] and a patient with a
heterozygous AIPmut [EBV-LC-AIP_p.R304*]) were treated
with cycloheximide (CHX, 100 g/mL) and total protein was
extracted at various time points for Western blot (WB). RNA
stability was analyzed using RT-qPCR. FifteenAIP variant plas-
mids (obtained by site-directed mutagenesis, Tables 1 and 2)
were transfected into HEK293 cells for half-life experiments
(CHX, 20 g/mL, Table 2), in the presence or absence of the
proteasome inhibitor MG-132 (20 M). Genetic and clinical
data were collected from 100 pituitary adenoma patients [60
from our cohort (4) and 40 cases reported in the literature] car-
rying themissenseAIP variants as well as the nonsensemutation
we have studied here. AIP interacting partners were identified in
a pull-down assay from rat GH-secreting GH3 cells using glu-
tathione-S-transferase-fusedWT and mutant AIP synthetic pro-
teins followed by quantitative mass spectrometry. Coimmuno-
precipitation and siRNAknockdown (KD) ofFBXO3were used
to study the role of FBXO3 in AIP degradation. Half-life exper-
iments were analyzed using a one-phase decay equation, and the
degradation speed (K) was compared between each mutant pro-
tein and the WT protein using the extra sum-of-squares F test.
Correlation between half-life and clinical features was analyzed
using data derived from studies listed in Table 3 using the Spear-
man R test. For other analyses, Kruskal-Wallis, one-way
ANOVA, and linear regression tests were used as appropriate,
and significance was taken as P  .05.
Results
The half-life of endogenous AIP is constant in
different cell lines
Under the experimental conditions used, the half-life of
endogenous AIP in CHX-treated HEK293 and EBV-LC-
AIP_WTcellswas significantly shorter comparedwith the
dimethylsulfoxide (DMSO) controls (P .0001 for both
cell lines, Figure 1A). The half-life of AIP was not signif-
icantly different between the two cell lines (HEK293,
43.5hvsEBV-LC-AIP_WT,32.7h;P .2537;Figure1B).
AIP half-life was practically identical between EBV-
LC-AIP_WT and EBV-LC-AIP_p.R304* cells (33.2 h for
AIP_p.R304*; Figure 1C). Assuming biallelic expression,
bands of 37.6 kDa for WT AIP and 34.5 kDa for the
truncated protein AIP p.R304* (as calculated by the Ex-
pasy Compute pI/Mw tool) (16) were expected in the WB
images for the EBV-LC-AIP_p.R304* cells. However, the
band for themutant proteinwas not detected (Figure 1D),
indicating that the mutant protein is either not expressed
or very rapidly degraded. The basal expression of theWT
AIP protein was significantly lower in the EBV-LC-
AIP_p.304* cells (49  17% of the level in the AIP_WT
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cells; P  .0006; Figure 1E) in agreement with the above
finding for the p.R304*mutant. Nevertheless, the finding
that the half-life of the WT protein is normal in these
mutant cells excludes the possibility of a dominant-nega-
tive effect of the heterozygous nonsense mutation on the
stability of WT AIP.
The absence of the mutant AIP p.R304* protein is
due to posttranslational regulation
The basal expression of AIP was not significantly
different between EBV-LC-AIP_WT and EBV-LC-
AIP_p.R304* cells, measured by qPCR (WT; 1.1; in-
terquartile range, [IQR], 0.6–1.3 vs p.R304*, 0.6; IQR,
0.5–2.2; P  .7; Figure 1F) and conventional RT-PCR
band densitometry (WT, 0.9; IQR, 0.9–1.1; vs
p.R304*, 1; IQR, 1–1.2; Figure 1G). Furthermore, the
presence of the mutant allele was confirmed by cDNA
sequencing (Figure 1H). These results suggest that both
the mutant and the WT allele are equally expressed at
the mRNA level; therefore, the lack of expression of the
mutant protein should be due to posttranslational
regulation.
Table 2. Half-life of Overexpressed AIP (WT and Variants) in HEK293 Cells
Variant Location in Protein
Half-Life Transfected
Protein, h
Degradation
Speed, K
P Value, K
Versus WT K
c.47GA (p.R16H) N terminus 94.2 0.0074 .0512
c.145GA (p.V49M) PPIase domain 27.0 0.0257 .0359
c.509TC (p.M170T) Between PPIase and
TPR1 domains
66.6 0.0104 .2931
c.562CT (p.R188W) TPR1 domain 21.0 0.0331 <.0001
c.713GA (p.C238Y) TPR2 domain 5.5 0.1270 <.0001
c.760 TC (p.C254R) TPR2 domain 4.7 0.1467 <.0001
c.762CG (p.C254W) TPR2 domain 8.4 0.0830 <.0001
c.769AG (p.I257V) TPR2 domain 28.7 0.0241 .0222
c.811CT (p.R271W) TPR3 domain 8.2 0.0849 <.0001
c.827CT (p.A276V) TPR3 domain 7.2 0.0957 <.0001
c.871GA (p.V291M) TPR3 domain 11.2 0.0621 <.0001
c.896CT (p.A299V) TPR3 domain 21.6 0.0321 .0002
c.911GA (p.R304Q) TPR3 domain 58.7 0.0118 .5644
c.910CT (p.R304*) C-terminal -helix 5.9 0.1183 <.0001
c.974GA (p.R325Q) C-terminal -helix 88.8 0.0078 .0948
Bold characters in the last column denote statistically significant values.
Table 1. Missense Variants Included in the Study
Variant Location in Protein Pathogenic Effect on Protein Structure
c.47GA (p.R16H) N terminus No No effect, residue out in solvent
c.145GA (p.V49M) PPIase domain Unlikely Out in solvent, strange for a hydrophobic change. Probably
involved in interactions
c.509TC (p.M170T) Between PPIase and
TPR1 domains
Likely No structure availablea
c.562CT (p.R188W) TPR1 domain Likely No prediction available
c.713GA (p.C238Y) TPR2 domain Yes Mutation causes severe steric clashes, disrupts packing of
hydrophobic core (5)
c.760 TC (p.C254R) TPR2 domain Likely No prediction available
c.762CG (p.C254W) TPR2 domain Likely No prediction available
c.769AG (p.I257V) TPR2 domain Likely Disrupts packing of hydrophobic core (5)
c.811CT (p.R271W) TPR3 domain Yes Involved in packing with numerous polar interactions. Tryptophan
at this position is likely to be disruptive (5)
c.827CT (p.A276V) TPR3 domain Unlikely Involved in packing, some steric clash with a valine residue, but
difficult to draw a definitive conclusion on the effect
c.871GA (p.V291M) TPR3 domain Likely Disrupts packing of hydrophobic core (forms base of hydrophobic
pocket interacting with bound peptide) (5)
c.896CT (p.A299V) TPR3 domain Unlikely At start of C-terminal -7 helix and may disrupt some small
degree of packing with L292 (5)
c.911GA (p.R304Q) TPR3 domain Yes Not involved in packing, but probably required for client protein
interaction (5)
c.974GA (p.R325Q) C-terminal -helix Likely Part of the C-terminal -7 helix, may affect client protein binding (5)
a This residue is neither included in the nuclear magnetic resonance spectroscopy structure of the peptidylprolyl cis-trans isomerase (PPIase)
domain, nor in the crystal structure of the TPR domain.
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Variable half-life of overexpressed WT AIP and
missense variants
Wecompared thehalf-life of theoverexpressedWTAIP
protein in HEK293 cells (48 h; Figure 2A) with that of
several AIP variants (Figure 2B and Table 2). The variants
p.R16H, p.M170T, p.R304Q, and p.R325Q behaved as
stable proteins, with half-life similar to that of the WT
protein (median, 77.7 h; IQR, 60.7–92.9; Figure 2C). The
rest of the missense variants displayed shortened half-life
when compared with the WT protein. A group of mutant
proteins (p.V49M, p.I257V, p.A299V) was considered to
have a “short” half-life (27 h; IQR, 21.6–28.7), because
the difference between their degradation speed (K) and
that of theWT protein resulted in P .05 but P 0.0001
(Figure 2D). Variants whose K displayed maximum sta-
tistical significance (P .0001) when compared with the
WTproteinwere considered tohave“very short”half-life:
p.R188W, p.C238Y, p.C254R, p.C254W, p.R271W,
p.A276V, p.V291M (7.7 h; IQR, 5.6–10.5; Figure 2E).
The variants with the shortest half-lives (p.C238Y and
p.C254R) were located in the second TPR motif of the
protein.
The pathogenic nonsense AIP variant p.R304* had a
“very short” half-life (5.9 h), in concordancewith the pro-
posed unstable behavior of this variant (3, 17). Interest-
ingly, all the missense variants with “very short” half-life,
except p.R188W and p.V291M, had degradation speeds
comparablewith that of the p.R304* variant (Figure 2F and
Supplemental Table 1). Also similar to p.R304*, their deg-
radation curves were characterized by a fast decay of the
protein in the first6hours, followedbyaplateau. Incontrast,
the curves for p.R188W and p.V291M displayed gradual
decay throughout the duration of the experiment, similar in
shape to that of the variants with “short” half-life.
Short-lived AIP variants are partially rescued by
proteasome inhibition
Stable WT AIP protein levels were found under pro-
teasome inhibition with MG-132, with minimal, but not
significant increase at 0, 6, 12, and 24 hours of treatment
(fold change at 24 h: 1.1; global P  .3592; Figure 3A).
Likewise, levels of the AIP variants p.R188W and
p.V291Mremained stable,whereas the levels of the rest of
the variants studied, including the p.R304*nonsense vari-
ant, significantly increased in response to MG-132.
Pooling all these results together, a significant negative
correlation was found between protein half-life and pro-
tein levels at 6 (r  0.6279), 12 (r  0.8292), and 24
hours (r0.8022) ofMG-132 treatment (P .0001 for
all the time points; Figure 3B), meaning that proteins with
shorter half-life displayed a more-dramatic response to
MG-132. These findings confirm that WT AIP is a stable
protein, whose degradation is driven by the ubiquitin pro-
teasome system (UPS), and that enhanced proteasomal
degradation is responsible for the reduced half-life shown
by some missense variants.
After the treatmentofEBV-LC-AIP_p.R304*cellswith
theproteasome inhibitorMG-132 for3or6hours, theWB
images displayed an additional band with a slightly faster
migration, compared with the WT protein (Figure 3C). A
third extra band, below the second one, was present at 0
hours and disappeared after treatment with the protea-
some inhibitor. Although both of these bands could rep-
resent degradation products, one of them could account
for AIP p.R304*, considering its apparent molecular
weight.
Correlating protein half-life and phenotype
Clinical data from 100 pituitary adenoma patients car-
rying the missense AIP variants and the nonsense variant
Table 3. Missense AIP Variants and nonsense p.R304* variant in Pituitary Adenoma Patients: Clinical Features
Variant
No. of Cases
Clinical
Presentation
Sex,
M/F
Age at Onset,
Median (IQR)
Age at Diagnosis,
Median (IQR)
Macro/
Micro, No. References
Our
Cases
Other
Cases Total
c.509TC (p.M170T) 0 1 1 Simplex 1/0 NA 32 NA (21)
c.562CT (p.R188W) 1 0 1 Simplex 1/0 10 12 1/0 Current report
c.713GA (p.C238Y) 3 0 3 Familial 3/0 20 (18–22) 21 (19–23) 2/0 (3,4,43)
c.760TC (p.C254R) 1 0 1 Simplex 0/1 14 17 1/0 Current report
c.762CG (p.C254W) 2 0 2 Familial 1/1 26 (21–31) 28 (23–33) 1/0 Current report
c.769AG (p.I257V) 0 1 1 Simplex 1/0 NA NA NA (44)
c.811CT (p.R271W) 1 8 9 Both 7/2 15.5 (12.8–18.3) 22 (14–28) 9/0 (2,4,25,45,46)
c.871GA (p.V291M) 0 1 1 Simplex 0/1 NA 30 NA (47)
c.911GA (p.R304Q) 13 8 21 Both 6/13# 27 (22–37) 36 (24.3–39.5) 14/3 (3,4,21,24,25,46–50)
c.910CT (p.R304*) 39 18 57 Both 31/26 17 (15–25.8) 19.5 (17–28.5) 43/5 (3,4,21,25,46,49–53)
c.974GA (p.R325Q) 0 3 3 Both 1/2 16 (7–33) 18 (16–35) 3/0 (21,54)
Total 60 40 100 52/46 18 (15–27) 23 (17–32) 73/8
Abbreviations: Macro/micro: macroadenomas/microadenomas; NA, not applicable.
Age at onset and at diagnosis is expressed in years.
# Gender was not available in two cases.
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Figure 1. Half-life of endogenous AIP in different cell lines. A, The measured AIP half-life in CHX-treated HEK293 and EBV-LC-AIP_WT cells was
significantly shorter compared with DMSO controls in HEK293 and EBV-LC-AIP_WT cells (P  .0001 for both cell lines), confirming that the
findings under these experimental conditions are due to the effect of CHX. ACTB, beta-actin. B, AIP half-life in HEK293 cells was not significantly
different than the half-life in EBV-LC-AIP_WT. C, AIP half-life was almost identical in EBV-LC-AIP_WT and EBV-LC-AIP_p.304* cells, when
considering band densitometry for the normal protein. D, In the half-life experiment using the EBV-LC-AIP_p.304* cells, the band for the p.R304*
mutant (expected mass, 34.5 kDa) was not detected. In the representative WB images, the top panels are for the experiments with CHX and
DMSO in HEK293 cells and the bottom panels are for EBV-LC-AIP_WT cells. WB bands for AIP (37.6 kDa) and the loading control beta-actin
(ACTB) (41.7 kDa) are shown in each case. E, Protein quantification in basal conditions demonstrates a reduced level of the normal AIP protein in
the EBV-LC-AIP_p.R304* cells, compared with the WT cell line. The differential expression of AIP observed in the two cell lines should be due to
posttranslational regulation, the basal AIP mRNA levels are not different between the two cell lines, quantified by (F) RT-qPCR and (G)
semiquantitative RT-PCR band densitometry. H, In concordance with these findings, the mutant cell line displays heterozygosity for AIP c.910CT
at the cDNA level.
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included in the half-life experiments were collected (Table
3). The variants c.47GA (p.R16H), c.145GA
(p.V49M), and c.896CT (p.A299V) were not included
in this clinical analysis, given that they are not considered
pathogenic based on previous clinical and functional eval-
uations. The variant c.827CT (p.A276V) was also ex-
cluded, given that it has never been found in pituitary
adenoma patients (detected only in a screening for AIP
Figure 2. Half-life of WT AIP and variants, overexpressed in HEK293 cells. A, Half-life curve for WT AIP. B, Half-life curves for all the variants
studied, compared with WT AIP. Comparisons with the WT protein were established by means of the degradation speed (K) calculated from each
half-life curve. C, Half-life curves for AIP variants with normal half-life (p.R16H, p.M170T, p.R304Q, and p.R325Q) and representative WB images,
compared with WT AIP. D, Half-life curves for AIP variants with “short” half-life (p.V49M, p.I257V, p.A299V) and representative WB images,
compared with WT AIP. E, Half-life curves for missense AIP variants with “very short” half-life (p.R188W, p.C238Y, p.C254R, p.C254W, p.R271W,
p.A276V, p.V291M) and representative WB images, compared with the WT protein. F, Half-life curves for variants with half-life similar to the
nonsense variant p.R304* (p.C238Y, p.C254R, p.C254W, p.R271W, p.A276V) and representative WB images, compared with AIP p.R304*.
Myc-AIP, 39 kDa; Myc-AIP p.R304*, 35.8 kDa; ACTB, 41.7 kDa. ACTB loading control shown for the WT experiment in each case.
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Figure 3. Blocking of proteasomal degradation with MG-132 (“rescue experiments”) and implications of AIP half-life for the phenotype in
pituitary adenoma patients. A, Curves of protein contents for the experiments with the variants and WT protein, expressed as percentages (level at
the 24-h time point was considered as 100% for each protein) or as fold change from time 0 (time 0  1) and representative WB images. The AIP
variants p.R188W (fold change at 24 h, 1.1; global P  .5080) and p.V291M (fold change at 24 h, 1.4; global P  .1263) were stable. In contrast,
levels of the other variants studied displayed a significant rise in response to MG-132: p.C238Y (fold change, 1.6 [P  .0403]; 2.5 [P  .0170]; and
2.1 [P  .0015] at 6, 12, and 24 h, respectively), p.C254R (fold change, 1.6 [P  .0087]; 2.3 [P  .0008]; and 2.6 [P  .0094]), p.C254W (fold
change, 1.4 [P  .0910]; 1.5 [P  .0006]; and 1.7 [P  .0087]), p.R271W (fold change, 1.4 [P  .1796]; 1.5 [P  .0229]; and 1.7 [P  .0676]),
p.A276V (fold change, 1.9 [P  .0072]; 2.5 [P  .0120]; and 3.9 [P  .0225]) and p.R304* (fold change, 1.6 [P  .0055]; 2 [P  .0041]; and 2.4
[P  .0001]). Myc-AIP, 39 kDa; Myc-AIP p.R304*, 35.8 kDa; ACTB, 41.7 kDa. ACTB loading control shown for the WT experiment in each case.
B, Correlation between half-life and fold change after MG-132 treatment at 6, 12, and 24 h. A significant indirect correlation was found at the three
time points, indicating proteins with shorter half-lives responded better to proteasome inhibition. C, MG-132 treatment of EBV-LC-AIP_p.R304*
cells. In the AIP WB (using 40 g of total protein) the strongest band (arrow) corresponds to the WT protein (37.6 kDa). Two faint extra bands can
be observed: a first band that is absent at time 0 and appears after the treatment with MG-132 (top arrowhead) and a second, lower band
(bottom arrowhead), which is more evident at time 0. Although both bands could correspond to degradation products, the heaviest one could
possibly be given by a small amount of truncated protein, appearing after proteasomal degradation is inhibited (expected size, 34.5 kDa). Loading
control: ACTB (41.7 kDa). D, The half-life of the studied AIP variants directly correlated with the age at diagnosis, (E) even when excluding patients
with the p.R304* mutant; (F) the significance increased when considering only patients with acromegaly or gigantism.
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single-nucleotide polymorphisms in DNA samples from
different populations) (18).
Adirect correlationwas foundbetweenageat diagnosis
and protein half-life (r 0.3180; P .0015; Figure 3D).
This remained significant after excludingpatients carrying
the p.R304* nonsense variant (r  0.3478; P  .0259;
Figure 3E). As AIPmuts are mainly prevalent among pa-
tients with GH excess (acromegaly or gigantism), we an-
alyzed this group separately, finding also a significant cor-
relation between age at diagnosis and protein half-life (r
0.411; P  .002; Figure 3F). The proportion of patients
withmacroadenomas (vsmicroadenomas)was similar for
the variants with “very short” half-life compared with
other variants (91.8 vs 85%; P  .4007).
The SKP1–CUL1–F-box protein (SCF) E3 ubiquitin-
ligase complex containing the FBXO3 regulates AIP
half-life
Two members of the SCF E3 ubiquitin-ligase complex
were detected by our pull-down experiments: the F-box
containing protein FBXO3 and SKP1, with differential
representation among different pull-down experiments
(Supplemental Figure 1A). Validation by coimmunopre-
cipitation with WT AIP was positive only for FBXO3
(Supplemental Figure 1B); however, if AIP is directed to
ubiquitination by the SCF complex, it is expected to in-
teract with FBXO3 and not with SKP1. In concordance
with this, stable endogenous AIP levels were found when
FBXO3 was partially silenced by KD (Supplemental Fig-
ure 2),whereasFBXO3overexpression resulted in a curve
resembling that of the untransfected cells. The scrambled
siRNA control resulted in slightly reduced K, whereas the
rescue experiment rendered results similar to those of the
KD, although no statistically significant differences were
found. Nevertheless, the K obtained in these experiments
was directly influenced by the level of FBXO3 expression,
as shown by linear regression (r2 0.7915; P .0001).
These results suggest thatAIP is targeted andboundby the
SCF E3 ubiquitin-ligase complex, via the F-box-contain-
ing protein, FBXO3, to be degraded by the UPS. The dif-
ferential affinity in thepull-downexperiment suggests that
the p.R304* mutant is more prone to be ubiquitinated
than the WT protein.
Discussion
We measured the half-life of 15 AIP variants and estab-
lished that most of the pathogenic missense mutants
have a short or very short half-life. Furthermore, the
half-life of mutant proteins correlated with age at di-
agnosis of acromegaly/gigantism in the patients harbor-
ing these mutations.
The maintenance of intracellular proteostasis relies on
the correct functioning of complex cotranslational and
posttranslationalmechanisms todetermine the fateofpro-
teins (repair vs degradation), a process often referred to as
“protein quality control” (19). Protein and mRNA half-
lives are strictly regulated: usually genes with constitutive
cell functions have both stable mRNAs and proteins,
whereas transcription factors, signaling molecules, chro-
matin-modifying enzymes, and genes with cell cycle–spe-
cific functions tend tohave unstablemRNAsandproteins;
abundant and highly structured proteins are more stable
than the less-abundant and less-structured ones (20). Not
surprisingly, under the experimental conditions used, the
abundantly expressed cochaperone AIP behaved as a sta-
ble protein, with a half-life of 32.7–43.5 hours. The half-
life of endogenous humanAIP (32.7 h) was very similar to
the reported half-life for themouseAIP (30.4 h),measured
by stable isotope labeling by amino acids in cell culture in
NIH 3T3 cells (20).
For most of the AIP variants we studied, the pathoge-
nicity predictions matched the half-life results (ie, patho-
genic variants had very short half-life). However, given
that the pathogenicmechanismsof variants are likely to be
variable, and there may not be a single in vitro method to
identify pathogenicity of all the missense mutants, we ob-
served some discrepancies. Only one of the four normal
half-life variants is currently considered nonpathogenic
(p.R16H), whereas the other three (p.M170T, p.R304Q,
p.R325Q) were suggested to be pathogenic. The variant
p.M170T has only been reported in one patient with
young-onset acromegaly (21), there is no functional data
published and its minor allele frequency (MAF) is not
available in public databases. Besides the in silico predic-
tion and clinical data, no functional data are available for
p.R325Q (MAF 0.00006) (22). For the much more com-
mon variant, p.R304Q (21 patients andMAF0.0007 (23)
and 0.0015 (22) in two databases, including a homozy-
gous subject), although clinical data strongly supports a
pathogenic role, most of the experimental results are
against a negative effect on protein function (24, 25). If
these three variants are indeed pathogenic, themechanism
should be related to loss of a function that is independent
of protein stability. This is consistent with our previous
hypothesis that lack of client protein interaction is suffi-
cient for pituitary adenoma predisposition (5).
Our “short” half-life group (defined based on arbitrary
cutoffs for statistical significance) included three variants
with different predicted effects. The AIP variant p.A299V
[MAF 0.001 (23, 26) and 0.0004 (22)] is considered un-
likely pathogenic based on clinical data together with the
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results of different functional studies (3, 24, 25). In con-
trast, a damaging structural effect has been predicted for
p.I257V, given that this variant affects a well-conserved
amino acid in the second TPR domain of AIP (5, 27),
matching the clinical data, and therefore confirming its
pathogenic effect. In the case of p.V49M [MAF 0.0002
(22, 23)] the change of a hydrophobic (V) for a polar (M)
amino acid could possibly disrupt the folding of the PPIase
domain. Our half-life data support a pathogenic role for
this variant, detected in a simplex gigantism case, with no
LOH in the tumor (28).
The endogenous mutant protein could not be detected
in EBV-LC-AIP_p.R304* cells, but it apparently became
visible following proteasome inhibitor treatment, sup-
porting the findings of very unstable behavior for this C-
terminally truncated protein. Our experiments demon-
strate that the absence of detectable protein is due to a
posttranslational mechanism (proteasomal degradation),
given thatnonsense-mediatedmRNAdecaywas ruledout.
Protein interaction studies have shown a partial loss of
interaction with HSP90 and HSPA8 for this mutant (un-
published data by our group). As these chaperones facil-
itate the correct folding of their partner proteins, loss of
the AIP C-terminal interaction site could disrupt the fold-
ing of its TPRmotifs. This is supported by the fact that the
effect of this nonsense mutation on protein half-life was
similar to that of themissensemutations affecting theTPR
repeats 2 and 3. In addition, misfolding and the loss of
interactions with certain partners could make these pro-
teins more prone to ubiquitination and proteasomal deg-
radation. Some AIP TPR mutants that are unable to bind
HSP90 or to assemble AHR/HSP90 complexes have been
described to have a normal half-life. This suggests thatAIP
stability could be independent of HSP90 binding (29) and
other partners could stabilize the protein. Conversely, if a
short half-life is translated into an almost absent protein
under physiological conditions, it could be assumed that
the endogenously expressed missense variants with
“short” or “very short” half-life would be present also at
low or very low levels in the cells.
As AIPmuts have so far always been found in the
heterozygous state, a possible dominant-negative effect of
the mutant protein on normal AIP could be considered,
and our experiments provide data to address this issue. In
this regard, the half-life experiments have two different
implications. Firstly, the fact the half-life of theWTAIP is
normal in the presence of the p.R304* unstable variant
rules out the possibility of a dominant-negative effect of
this mutant protein, an effect that accounts, for example,
for the loss of tumor-suppressor function of TP53 (30).
Secondly, considering that the expression ofAIP is appar-
ently biallelic, the expression of both alleles might be nec-
essary for AIP to perform its tumor suppressor functions
under basal or stimulated conditions, and the reduction of
total AIP expression could be insufficient for an antitu-
morigenic effect in the pituitary gland (haploinsufficiency)
(31).Our study did not investigatewhether the apparently
pathogenic variants with normal half-life behave in a sim-
ilar way, or if in those cases the proteins are expressed at
normal levels, but interferewith the stability or functionof
the normal protein (ie, if they have dominant-negative
effect).
The half-life of the AIP variants studied directly corre-
lated with the age at diagnosis in pituitary adenoma pa-
tients carrying those mutations. This finding is important
and clinically significant, and contributes to the validation
of the half-life assay as a method for determining the
pathogenicity ofAIPmissense variants. In addition, it sug-
gests that the age at disease onset in the setting ofAIPmuts
can be determined by the amount of functional protein
available. The application of a protein stability assay as a
means to evaluate the pathogenic effect of missense vari-
ants has also been proposed forMEN1 (32, 33), and for
PRKAR1A (34), two genes implicated in endocrine tu-
mor-predisposing syndromes. Nevertheless, protein sta-
bility is a parameter that cannot be evaluatedwith routine
diagnostic histopathological procedures.Given thatAIP is
a stable protein, abundantly expressed in the pituitary
gland, the static image of the tissue obtained by immuno-
histochemistry might not be sensitive enough to detect
changes in the AIP protein levels due to enhanced degra-
dation, especially in tumors with no LOH.
Proteasomal degradationof proteins is facilitatedbyE3
ubiquitin ligases. The SCF, a multiprotein complex, is the
prototypical cullin-really interesting new gene (RING) E3
ubiquitin-ligase, consisting of the RING-containing en-
zymeRBX1, the cullin scaffoldCUL1, the adaptor protein
SKP1 and a variable F-box containing protein, the latter
defining the specificity of the protein degradation via the
UPS (35, 36). Our findings suggest that AIP is specifically
targeted by FBXO3 to be bound by the SCF E3 ubiquitin-
ligase complex and delivered to UPS. Although KD of
FBXO3 resulted in prolongedAIP half-life, this effect was
not statistically significant. This could be explained by the
influence of more than one E3 ubiquitin ligase on AIP
targeting, as it occurs for the tumor suppressor TP53 (37).
Dysfunction of the UPS pathway is related to a variety of
human disorders, either due to reduced or increased ubiq-
uitination of target proteins (38), including corticotroph ad-
enomas (39–41).Different stepsof theUPS represent targets
for recentlydevelopeddrugs for the treatmentofhumanneo-
plasms and other conditions (38). The proteasome inhibitor
MG-132actsat the chymotrypsin-like siteof theproteasome
(also at the caspase-like site at high concentrations), in a sim-
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ilarway to the clinically availableproteasome inhibitorbort-
ezomib (PS-341) (42). Proteasome inhibitors could theoret-
ically restore the levels ofmutant AIP, as it has recently been
proposedalso formenin (32), andcould thereforehavearole
in the treatment of aggressive pituitary adenomas.However,
the effects of these drugs include regulation ofmultiple path-
ways implicated in tumorigenesis, and therefore this possible
applicationshouldbeexploredindepth inpreclinical studies.
Conclusions
Human AIP is a stable protein whose degradation is driven
byubiquitinationandproteasomaldegradationmediatedby
the FBXO3-containing SCF E3 ubiquitin-ligase complex.
Most of the clinically relevant missenseAIP variants tested,
especially those affecting the TPRdomain of the protein, as
well as the nonsense mutant p.R304*, displayed re-
duced protein half-life due to enhanced proteasomal
degradation. These unstable proteins can be partially
rescued by proteasome inhibition. A direct significant cor-
relation between protein half-life and age at diagnosis in
AIPmut-positive pituitary patients was found. The coex-
istence of an unstable AIP mutant does not seem to affect
the half-life of the WT AIP protein. We describe here a
novel pathogenic mechanism of reduced half-life of AIP
mutants with close correlation with clinical parameters.
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